Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid

Proteomics - Clinical Applications

Volumn 5, Issue 3-4, 2011, Pages 167-178

  Perluigi, Marzia ^a   di Domenico, Fabio ^a   Fiorini, Ada ^a   Cocciolo, Annalisa ^a   Giorgi, Alessandra ^a   Foppoli, Cesira ^b   Butterfield, D Allan ^c   Giorlandino, Maurizio ^d   Giorlandino, Claudio ^d   Eugenia Schinina M ^a   Coccia, Raffaella ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF KENTUCKY   (United States)

^d Artemisia Fetal Maternal Medical Centre   (Italy)

Author keywords

Amniotic fluid; Down syndrome; Oxidative stress; Protein oxidation; Redox proteomics

Indexed keywords

ALPHA1 GLYCOPROTEIN; ALPHA2 GLYCOPROTEIN; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CERULOPLASMIN; COLLAGEN TYPE 4; COMPLEMENT COMPONENT C9; GLUTATHIONE; GLUTATHIONE DISULFIDE; HEAT SHOCK PROTEIN; LIPID; RETINOL BINDING PROTEIN 4; THIOREDOXIN; TRANSFERRIN;

AMNION FLUID ANALYSIS; ARTICLE; CAUSAL ATTRIBUTION; CONTROLLED STUDY; DOWN SYNDROME; ENZYME ASSAY; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; IRON METABOLISM; LIPID PEROXIDATION; MOLECULAR PATHOLOGY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PREGNANCY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CARBONYLATION; PROTEIN TARGETING; PROTEOMICS; WESTERN BLOTTING;

ADULT; AMNIOTIC FLUID; DOWN SYNDROME; FEMALE; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHENOTYPE; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PROTEINS; PROTEOMICS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 79953120069     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000121     Document Type: Article

References (74)

1. Tiano, L., Padella, L., Carnevali, P., Gabrielli, O. et al., Coenzyme Q10 and oxidative imbalance in Down syndrome: biochemical and clinical aspects. Biofactors 2008, 32, 161-167.
2. Roper, R. J., Reeves, R. H., Understanding the basis for Down syndrome phenotypes. PLoS Genet. 2006, 2, e50.
3. Pallardo, F. V., Degan, P., d'Ischia, M., Kelly, F. J. et al., Multiple evidence for an early age pro-oxidant state in Down syndrome patients. Biogerontology 2006, 7, 211-220.
4. Iannello, R. C., Crack, P. J., de Haan, J. B., Kola, I., Oxidative stress and neural dysfunction in Down syndrome. J. Neural Transm. Suppl. 1999, 57, 257-267.
5. Jovanovic, S. V., Clements, D., MacLeod, K., Biomarkers of oxidative stress are significantly elevated in Down syndrome. Free Radic. Biol. Med. 1998, 25, 1044-1048.
6. Zana, M., Janka, Z., Kalman, J., Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease. Neurobiol. Aging 2007, 28, 648-676.
7. Turrens, J. F., Increased superoxide dismutase and Down's syndrome. Med. Hypotheses 2001, 56, 617-619.
8. Halliwell, B., Biochemistry of oxidative stress. Biochem. Soc. Trans. 2007, 35, 1147-1150.
9. Balcz, B., Kirchner, L., Cairns, N., Fountoulakis, M., Lubec, G., Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J. Neural Transm. Suppl. 2001, 193-201.
10. Zitnanova, I., Korytar, P., Aruoma, O. I., Sustrova, M. et al., Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms? Clin. Chim. Acta 2004, 341, 139-146.
11. Perrone, S., Longini, M., Bellieni, C. V., Centini, G. et al., Early oxidative stress in amniotic fluid of pregnancies with Down syndrome. Clin. Biochem. 2007, 40, 177-180.
12. Nagyova, A., Sustrova, M., Raslova, K., Serum lipid resistance to oxidation and uric acid levels in subjects with Down's syndrome. Physiol. Res. 2000, 49, 227-231.
13. Arbuzova, S., Hutchin, T., Cuckle, H., Mitochondrial dysfunction and Down's syndrome. Bioessays 2002, 24, 681-684.
14. Kolialexi, A., Vrettou, C., Traeger-Synodinos, J., Burgemeister, R. et al., Noninvasive prenatal diagnosis of beta-thalassaemia using individual fetal erythroblasts isolated from maternal blood after enrichment. Prenat. Diagn. 2007, 27, 1228-1232.
15. Butterfield, D. A., Galvan, V., Lange, M. B., Tang, H. et al., In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic. Biol. Med. 2010, 48, 136-144.
16. Calabrese, V., Mancuso, C., Ravagna, A., Perluigi, M. et al., In vivo induction of heat shock proteins in the substantia nigra following L-DOPA administration is associated with increased activity of mitochondrial complex I and nitrosative stress in rats: regulation by glutathione redox state. J. Neurochem. 2007, 101, 709-717.
17. Levine, R. L., Williams, J. A., Stadtman, E. R., Shacter, E., Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 1994, 233, 346-357.
18. Di Domenico, F., Perluigi, M., Foppoli, C., Blarzino, C. et al., Protective effect of ferulic acid ethyl ester against oxidative stress mediated by UVB irradiation in human epidermal melanocytes. Free Radic. Res. 2009, 43, 365-375.
19. Perluigi, M., Giorgi, A., Blarzino, C., De Marco, F. et al., Proteomics analysis of protein expression and specific protein oxidation in human papillomavirus transformed keratinocytes upon UVB irradiation. J. Cell. Mol. Med. 2009, 13, 1809-1822.
20. Perluigi, M., Di Domenico, F., Blarzino, C., Foppoli, C. et al., Effects of UVB-induced oxidative stress on protein expression and specific protein oxidation in normal human epithelial keratinocytes: a proteomic approach. Proteome Sci. 2010, 8, 13.
21. Maurer, H. H., Peters, F. T., Toward high-throughput drug screening using mass spectrometry. Ther. Drug Monit. 2005, 27, 686-688.
22. Canettieri, G., Di Marcotullio, L., Greco, A., Coni, S. et al., Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat. Cell Biol. 2010, 12, 132-142.
23. Pappin, D. J., Peptide mass fingerprinting using MALDI-TOF mass spectrometry. Methods Mol. Biol. 2003, 211, 211-219.
24. Lauderback, C. M., Hackett, J. M., Huang, F. F., Keller, J. N. et al., The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J. Neurochem. 2001, 78, 413-416.
25. Odetti, P., Angelini, G., Dapino, D., Zaccheo, D. et al., Early glycoxidation damage in brains from Down's syndrome. Biochem. Biophys. Res. Commun. 1998, 243, 849-851.
26. Busciglio, J., Yankner, B. A., Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995, 378, 776-779.
27. Demple, B., A bridge to control. Science 1998, 279, 1655-1656.
28. Rietsch, A., Beckwith, J., The genetics of disulfide bond metabolism. Annu. Rev. Genet. 1998, 32, 163-184.
29. Hancock, J. T., Desikan, R., Neill, S. J., Does the redox status of cytochrome C act as a fail-safe mechanism in the regulation of programmed cell death? Free Radic. Biol. Med. 2001, 31, 697-703.
30. Bains, J. S., Shaw, C. A., Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Brain Res. Rev. 1997, 25, 335-358.
31. Sen, C. K., Cellular thiols and redox-regulated signal transduction. Curr. Top. Cell. Regul. 2000, 36, 1-30.
32. Gulesserian, T., Seidl, R., Hardmeier, R., Cairns, N., Lubec, G., Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J. Investig. Med. 2001, 49, 41-46.
33. Andersen, J. K., Oxidative stress in neurodegeneration: cause or consequence? Nat. Med. 2004, 10, S18-S25.
34. Qian, Y., Falahatpisheh, M. H., Zheng, Y., Ramos, K. S., Tiffany-Castiglioni, E., Induction of 78kD glucose-regulated protein (GRP78) expression and redox-regulated transcription factor activity by lead and mercury in C6 rat glioma cells. Neurotox. Res. 2001, 3, 581-589.
35. Calabrese, V., Sultana, R., Scapagnini, G., Guagliano, E. et al., Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid. Redox Signal. 2006, 8, 1975-1986.
36. Tyrrell, R., Redox regulation and oxidant activation of heme oxygenase-1. Free Radic. Res. 1999, 31, 335-340.
37. Mancuso, C., Heme oxygenase and its products in the nervous system. Antioxid. Redox Signal. 2004, 6, 878-887.
38. Poon, H. F., Calabrese, V., Scapagnini, G., Butterfield, D. A., Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J. Gerontol. A Biol. Sci. Med. Sci. 2004, 59, 478-493.
39. Yoo, B. C., Fountoulakis, M., Dierssen, M., Lubec, G., Expression patterns of chaperone proteins in cerebral cortex of the fetus with Down syndrome: dysregulation of T-complex protein 1. J. Neural Transm. Suppl. 2001, 321-334.
40. Yoo, B. C., Vlkolinsky, R., Engidawork, E., Cairns, N. et al., Differential expression of molecular chaperones in brain of patients with Down syndrome. Electrophoresis 2001, 22, 1233-1241.
41. Engidawork, E., Lubec, G., Molecular changes in fetal Down syndrome brain. J. Neurochem. 2003, 84, 895-904.
42. Tsangaris, G. T., Karamessinis, P., Kolialexi, A., Garbis, S. D. et al., Proteomic analysis of amniotic fluid in pregnancies with Down syndrome. Proteomics 2006, 6, 4410-4419.
43. Park, J., Cha, D. H., Jung, J. W., Kim, Y. H. et al., Comparative proteomic analysis of human amniotic fluid supernatants with down syndrome using mass spectrometry. J. Microbiol. Biotechnol. 2010, 20, 959-967.
44. Cho, C. K., Smith, C. R., Diamandis, E. P., Amniotic fluid proteome analysis from Down syndrome pregnancies for biomarker discovery. J. Proteome Res. 2010, 9, 3574-3582.
45. Kolialexi, A., Tsangaris, G. T., Mavrou, A., Proteomics in prenatal diagnosis. Expert Rev. Proteomics 2009, 6, 111-113.
46. Mange, A., Desmetz, C., Bellet, V., Molinari, N. et al., Proteomic profile determination of autosomal aneuploidies by mass spectrometry on amniotic fluids. Proteome Sci. 2008, 6, 1.
47. Bielli, P., Calabrese, L., Structure to function relationships in ceruloplasmin: a 'moonlighting' protein. Cell. Mol. Life Sci. 2002, 59, 1413-1427.
48. Kang, J. H., Kim, K. S., Choi, S. Y., Kwon, H. Y., Won, M. H., Oxidative modification of human ceruloplasmin by peroxyl radicals. Biochim. Biophys. Acta 2001, 1568, 30-36.
49. Aouffen, M., Paquin, J., Furtos, A., Waldron, K. C., Mateescu, M. A., Oxidative aggregation of ceruloplasmin induced by hydrogen peroxide is prevented by pyruvate. Free Radic. Res. 2004, 38, 19-26.
50. Lee, P. D., Giudice, L. C., Conover, C. A., Powell, D. R., Insulin-like growth factor binding protein-1: recent findings and new directions. Proc. Soc. Exp. Biol. Med. 1997, 216, 319-357.
51. Miell, J. P., Jauniaux, E., Langford, K. S., Westwood, M. et al., Insulin-like growth factor binding protein concentration and post-translational modification in embryological fluid. Mol. Hum. Reprod. 1997, 3, 343-349.
52. Lassarre, C., Hardouin, S., Daffos, F., Forestier, F. et al., Serum insulin-like growth factors and insulin-like growth factor binding proteins in the human fetus. Relationships with growth in normal subjects and in subjects with intrauterine growth retardation. Pediatr. Res. 1991, 29, 219-225.
53. Langford, K., Blum, W., Nicolaides, K., Jones, J. et al., The pathophysiology of the insulin-like growth factor axis in fetal growth failure: a basis for programming by undernutrition? Eur. J. Clin. Invest. 1994, 24, 851-856.
54. Sara, V. R., Gustavson, K. H., Anneren, G., Hall, K., Wetterberg, L., Somatomedins in Down's syndrome. Biol. Psychiatry 1983, 18, 803-811.
55. Tham, A., Nordberg, A., Grissom, F. E., Carlsson-Skwirut, C. et al., Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J. Neural Transm. Park. Dis. Dement. Sect. 1993, 5, 165-176.
56. Torres-Aleman, I., Barrios, V., Lledo, A., Berciano, J., The insulin-like growth factor I system in cerebellar degeneration. Ann. Neurol. 1996, 39, 335-342.
57. Hirai, K., Hussey, H. J., Barber, M. D., Price, S. A., Tisdale, M. J., Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res. 1998, 58, 2359-2365.
58. Kanai, M., Raz, A., Goodman, D. S., Retinol-binding protein: the transport protein for vitamin A in human plasma. J. Clin. Invest. 1968, 47, 2025-2044.
59. Tsutsumi, C., Okuno, M., Tannous, L., Piantedosi, R. et al., Retinoids and retinoid-binding protein expression in rat adipocytes. J. Biol. Chem. 1992, 267, 1805-1810.
60. Hawn, J., Rice, C., Nichols, H., McDermott, S., Overweight and obesity among children with Down syndrome: a descriptive study of children attending a Down syndrome clinic in South Carolina. J. S. C. Med. Assoc. 2009, 105, 64-68.
61. Fagan, A. M., Christopher, E., Taylor, J. W., Parsadanian, M. et al., ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. Am. J. Pathol. 2004, 165, 1413-1422.
62. Plump, A. S., Azrolan, N., Odaka, H., Wu, L. et al., ApoA-I knockout mice: characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes. J. Lipid Res. 1997, 38, 1033-1047.
63. Williamson, R., Lee, D., Hagaman, J., Maeda, N., Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc. Natl. Acad. Sci. USA 1992, 89, 7134-7138.
64. Helbecque, N., Codron, V., Cottel, D., Amouyel, P., An apolipoprotein A-I gene promoter polymorphism associated with cognitive decline, but not with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2008, 25, 97-102.
65. Bloemers, B. L., van Bleek, G. M., Kimpen, J. L., Bont, L., Distinct abnormalities in the innate immune system of children with Down syndrome. J. Pediatr. 2010, 156, 804-809, 809 e801-809 e805.
66. Kusters, M. A., Verstegen, R. H., Gemen, E. F., de Vries, E., Intrinsic defect of the immune system in children with Down syndrome: a review. Clin. Exp. Immunol. 2009, 156, 189-193.
67. Coffman, L. G., Brown, J. C., Johnson, D. A., Parthasarathy, N. et al., Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294, L505-515.
68. Colman, R. W., Schmaier, A. H., Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997, 90, 3819-3843.
69. Gustafson, E. J., Schmaier, A. H., Wachtfogel, Y. T., Kaufman, N. et al., Human neutrophils contain and bind high molecular weight kininogen. J. Clin. Invest. 1989, 84, 28-35.
70. Baba, S. P., Patel, D. K., Bano, B., Modification of sheep plasma kininogen by free radicals. Free Radic. Res. 2004, 38, 393-403.
71. Lott, I. T., Head, E., Down syndrome and Alzheimer's disease: a link between development and aging. Ment. Retard. Dev. Disabil. Res. Rev. 2001, 7, 172-178.
72. Hayes, A., Batshaw, M. L., Down syndrome. Pediatr. Clin. North. Am. 1993, 40, 523-535.
73. Rabin, K. R., Whitlock, J. A., Malignancy in children with trisomy 21. Oncologist 2009, 14, 164-173.
74. Park, E., Alberti, J., Mehta, P., Dalton, A. et al., Partial impairment of immune functions in peripheral blood leukocytes from aged men with Down's syndrome. Clin. Immunol. 2000, 95, 62-69.